Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Stock Is Crushing It Today

By Keith Speights – Updated May 5, 2020 at 11:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech reported great news for its lead pipeline candidate.

What happened

Shares of Akebia Therapeutics (AKBA -2.14%) were skyrocketing 37.3% higher as of 11:25 a.m. EDT on Tuesday. The huge jump came after the biotech announced positive results from a late-stage clinical study for its lead pipeline candidate vadadustat and reported its first-quarter financial results.

So what

The most important news for Akebia by far was its clinical update for vadadustat. The late-stage clinical study found the drug to be safe and effective in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis in a head-to-head comparison with darbepoetin alfa, an approved drug marketed by Amgen under the brand name Aranesp.

Left hand holding a stethoscope and a clipboard with a drawing of a syringe dripping blood and the word "anemia" with the right hand holding a pen

Image source: Getty Images.

Akebia stated that vadadustat achieved both primary and key efficacy endpoints of the study, demonstrating non-inferiority to darbepoetin alfa in a mean change in hemoglobin levels. The drug also achieved the primary safety endpoint of the study, showing non-inferiority to darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE).

The good news for vadadustat completely overshadowed Akebia's Q1 financial update. But there was some good news on that front as well. Akebia reported total revenue of $88.5 million in the first quarter, up 22% year over year. The company also announced that its cash, cash equivalents, and available-for-sale securities totaled $115.4 million as of March 31. Akebia said that its cash position should carry it "well into 2021." 

Now what

There's one other important catalyst on the way for the biotech stock. Akebia expects to report results in mid-2020 from its second late-stage study of vadadustat in treating patients not on dialysis with CKD-related anemia. The company plans to file for Food and Drug Administration approval of the drug soon afterward if all goes well. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics Stock Quote
Akebia Therapeutics
$0.32 (-2.14%) $0.01
Amgen Stock Quote
$233.82 (0.34%) $0.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.